Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Eric Gordon
AddedMar 31, 2024
UpdatedMay 31, 2026
Eric Gordon

Eric Gordon

Co-Founder, Arixa Pharmaceuticals

CrunchbaseLinkedIn

Eric Gordon's Career

Arixa Pharmaceuticals
Arixa Pharmaceuticals

Palo Alto, CA, US

Co-Founder
Atentiv
Atentiv

Waltham, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Eric Gordon's Career

Arixa Pharmaceuticals
Arixa Pharmaceuticals
Seed$13M302016Palo Alto, CA, US
Co-Founder

Leadership at Arixa Pharmaceuticals

John G. FreundJohn G. FreundCo-Founder

Similar to Arixa Pharmaceuticals

Aria PharmaceuticalsAria PharmaceuticalsPalo Alto, CA, USPharmaceuticalsest. 2014Aria PharmaceuticalsPalo Alto, CA, US · est. 2014

Aria Pharmaceuticals: Pioneering novel therapies for complex diseases in preclinical stages.

Series B · $14.3M38
X-Biotix TherapeuticsX-Biotix TherapeuticsWaltham, MA, USAntibioticsest. 2016X-Biotix TherapeuticsWaltham, MA, US · est. 2016

X-Biotix Therapeutics: A biotech firm innovating antibiotic solutions for multi-drug-resistant pathogens.

Series A · $7M9
Synereca PharmaceuticalsSynereca PharmaceuticalsChapel Hill, NC, USDrugs, Pharmaceuticalsest. 2017Synereca PharmaceuticalsChapel Hill, NC, US · est. 2017

Synereca Pharmaceuticals innovates orally-active drugs to enhance existing antibiotics' effectiveness.

Pre-Seed · $2.3M6
Taxis PharmaceuticalsTaxis PharmaceuticalsMonmouth Junction, NJ, USPharmaceuticalsest. 2009Taxis PharmaceuticalsMonmouth Junction, NJ, US · est. 2009

TAXIS Pharmaceuticals Inc., a biopharmaceutical firm specializing in developing drugs for resistant bacterial pathogens.

Seed · $6.2M28
Atentiv
Atentiv
Seed$11.2M112012Waltham, MA, US
Board Member· Board

Leadership at Atentiv

John BrooksJohn BrooksBoard Member

Similar to Atentiv

MentavaMentavaTacoma, WA, USEducational Softwareest. 2021MentavaTacoma, WA, US · est. 2021

Mentava: A leading software company empowering top-performing students to reach their potential.

Seed · $3M4
Attention PointAttention PointRoanoke, VA, USADHD Assessment, Behavioral Healthest. 2012Attention PointRoanoke, VA, US · est. 2012

Health IT firm, Attention Point, provides web-based tools for behavioral health diagnosis, specializing in ADHD assessment.

Seed · $25k30
TeachTownTeachTownWoburn, MA, USEducational Softwareest. 2003TeachTownWoburn, MA, US · est. 2003

TeachTown, based in Woburn, US, offers specialized educational software for children with developmental disorders.

Private Equity · $5.6M115
AttentionAttentionNew York City, NY, USSales Softwareest. 2021AttentionNew York City, NY, US · est. 2021

NYC-based Attention offers AI-powered sales tools for real-time coaching, CRM auto-fill, and intelligent follow-ups, boosting revenue and efficiency.

Seed · $3.1M17

Eric Gordon's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Eric Gordon

Brian LongBrian LongBoard Member · NextView VenturesShiva DhawanShiva DhawanCo-Founder · AttentiveRob McInerneyRob McInerneyCo-Founder · IntelligentXSarthak VijaySarthak VijayCo-Founder · AttentiveDivyanshu JindalDivyanshu JindalCo-Founder · AttentiveTodd BermanTodd BermanFounder · EveryTeam